Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adjuvanted RZV vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo group | PLACEBO_COMPARATOR | Participants in this group receive placebo, the first dose being administered at Day 1 and the second dose at Month 2. |
| Adjuvanted RZV group | EXPERIMENTAL | Participants in this group receive the adjuvanted RZV vaccine, the first dose being administered at Day 1 and the second dose at Month 2. |
| Adjuvanted RSVPreF3 group | EXPERIMENTAL | Participants in this group receive a single dose of placebo at Day 1 and a single dose of the adjuvanted RSVPreF3 vaccine at Month 2. |
| Name | Type | Description |
|---|---|---|
| Placebo | COMBINATION_PRODUCT | Placebo will be administered intramuscularly. |
| Adjuvanted RZV vaccine | COMBINATION_PRODUCT | Adjuvanted RZV vaccine will be administered intramuscularly. |
| Adjuvanted RSVPreF3 vaccine | BIOLOGICAL | Adjuvanted RSVPreF3 vaccine will be administered intramuscularly. |
Inclusion Criteria: * Participants, including participants with a caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure....
Adjuvanted RZV vaccine is being studied for use in cardiovascular disease, specifically to explore its effect on coronary plaque progression in adults aged 50 years and older who are at risk for cardiovascular events. It is an investigational vaccine currently in Phase 2 clinical development.
Adjuvanted RZV vaccine is a vaccine modality designed to elicit an immune response. The specific molecular target is not disclosed in the available information. The ongoing trial evaluates its effect on coronary plaque progression in adults at risk for cardiovascular events.
Adjuvanted RZV vaccine is being developed by GSK plc, a biopharma company listed on the stock exchange under the ticker GSK. The company is conducting a Phase 2 clinical trial to evaluate the vaccine's effect on cardiovascular disease.
Adjuvanted RZV vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The ongoing Phase 2 trial is designed to explore its effect on coronary plaque progression in adults at risk for cardiovascular events.
Adjuvanted RZV vaccine is being evaluated in one Phase 2 clinical trial with the identifier NCT07712380. This randomized, double-blind, placebo-controlled study is investigating the effect of Adjuvanted RZV or RSVPreF3 vaccines on coronary plaque progression in adults aged 50 years and older at risk for cardiovascular events. The trial is not yet recruiting and plans to enroll 450 participants.